Our Pricing

Wegovy UK Online Prescription: Get Started in 3 Minutes

Accessing a wegovy uk online prescription has never been simpler — at Cured Pharmacy, our UK-registered clinical team can assess your suitability in under 3 minutes, with genuine Wegovy pens available from £79.00. No hidden fees, no waiting rooms, just transparent pricing and discreet home delivery across the UK.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone your body produces after eating [1]. By activating GLP-1 receptors in the brain, pancreas, and digestive system, semaglutide reduces appetite, slows gastric emptying, and improves blood sugar regulation — creating the physiological conditions for sustained weight loss.

In the landmark STEP 1 trial, adults using Wegovy achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo [1]. Nearly one-third of participants lost 20% or more of their starting weight, results that positioned semaglutide as one of the most effective pharmacological weight loss treatments licensed by the MHRA.

Unlike appetite suppressants that work solely on hunger signals, Wegovy addresses multiple metabolic pathways simultaneously. Patients typically report feeling fuller sooner, experiencing fewer food cravings, and finding it easier to maintain portion control — all without the jitteriness or stimulant effects associated with older weight loss medications [2].

Getting Your Wegovy UK Online Prescription at Cured Pharmacy

Our streamlined prescription process takes under 3 minutes to complete. You'll answer medically relevant questions about your weight history, current medications, and health conditions — the same information a GP would gather during an in-person consultation. Our UK-registered prescribers review every submission individually, ensuring Wegovy is clinically appropriate for your circumstances.

Once approved, your prescription is sent directly to our dispensary where superintendent pharmacist Tarun Kumar (GPhC 2233073) and his team prepare your medication. We source only genuine UK-licensed Wegovy pens, never grey-market imports or compounded alternatives. Every pen arrives in discreet packaging with full patient information leaflets and injection guidance.

Prescriptions are typically reviewed within hours during working days, with next-day delivery available across the UK. You'll see the exact price — from £79.00 depending on your prescribed dose — before completing your consultation, eliminating the pricing uncertainty common with other online services.

What Happens After Your Assessment

If your prescriber determines Wegovy isn't suitable based on your medical history, they'll explain why and may suggest alternative treatments. Common reasons for declining a prescription include recent cardiovascular events, personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2 [3]. This clinical oversight protects patient safety and ensures compliance with MHRA prescribing guidelines.

Approved patients receive detailed injection instructions, a dosing schedule showing the gradual titration from 0.25 mg to the maintenance dose, and guidance on managing common side effects. Our pharmacist team remains available by phone on (+44) 116 4646009 throughout your treatment for any questions or concerns.

Wegovy Dosing Schedule and What to Expect

Wegovy follows a carefully designed dose escalation protocol to minimise gastrointestinal side effects while your body adjusts to the medication [3]. You'll start with 0.25 mg once weekly for four weeks, then increase monthly through 0.5 mg, 1 mg, and 1.7 mg, reaching the maintenance dose of 2.4 mg by week 17. This gradual titration significantly reduces the nausea and vomiting that can occur when GLP-1 medications are started too quickly.

Each Wegovy pen contains a single pre-filled dose, eliminating the need to measure or draw up medication. The injection itself takes seconds — you'll use a different injection site each week, rotating between your abdomen, thigh, or upper arm. Most patients report the injection is virtually painless, with a finer needle than those used for insulin or other injectable medications.

Weight loss typically becomes noticeable within 4-8 weeks, with the most significant reductions occurring between weeks 20 and 60 of treatment [1]. Clinical trials showed weight loss plateaus around week 60, after which most patients maintain their reduced weight with continued weekly injections. Your prescriber will monitor your progress and may adjust your treatment plan if you're not achieving at least 5% weight loss by week 16.

Managing Side Effects During Treatment

Nausea is the most commonly reported side effect, affecting approximately 44% of patients in clinical trials, though it typically improves after the first few weeks [2]. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated can significantly reduce gastrointestinal discomfort. Most patients find these effects manageable and consider them a reasonable trade-off for the weight loss achieved.

Less common but more serious side effects include pancreatitis, gallbladder problems, and changes in vision for those with diabetes. Contact your prescriber immediately if you experience severe abdominal pain, persistent vomiting, or signs of an allergic reaction. These occur rarely but require prompt medical assessment.

Wegovy vs Other Weight Loss Treatments

Semaglutide (Wegovy) and liraglutide (Saxenda) both belong to the GLP-1 receptor agonist class, but semaglutide's longer half-life allows once-weekly dosing compared to Saxenda's daily injections [4]. In head-to-head comparisons, semaglutide produced significantly greater weight loss — 14.9% versus 7.8% with liraglutide over similar timeframes. The convenience of weekly rather than daily injections also improves long-term adherence.

Tirzepatide represents the newest generation of weight loss injectables, combining GLP-1 activity with glucose-dependent insulinotropic polypeptide (GIP) receptor activation. While not yet widely available in the UK for weight management, early trials suggest even greater weight loss potential than semaglutide alone. For most patients currently seeking treatment, Wegovy remains the gold standard based on its extensive clinical evidence and MHRA licensing for chronic weight management.

Oral medications like orlistat work through an entirely different mechanism — blocking fat absorption in the intestines rather than affecting appetite hormones. While orlistat can be effective, average weight loss is typically 5-7% compared to Wegovy's 15%, and gastrointestinal side effects related to unabsorbed fat can be troublesome [5]. Your prescriber will discuss which treatment best matches your medical history, weight loss goals, and lifestyle preferences.

Who Can Use Wegovy: Eligibility Criteria

NICE guidelines recommend considering GLP-1 treatments for adults with a BMI of 30 kg/m² or higher, or 27 kg/m² with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [6]. These thresholds ensure treatment is reserved for patients who will benefit most and for whom the clinical benefits outweigh potential risks.

Wegovy is contraindicated in pregnancy, during breastfeeding, and in patients under 18 years old. Those with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use semaglutide due to thyroid C-cell tumour risks observed in animal studies [3]. Your online assessment will screen for these contraindications before a prescription can be issued.

Patients currently using other GLP-1 medications for diabetes (such as Ozempic) should not use Wegovy concurrently, as both contain semaglutide and would result in excessive dosing. If you're already prescribed semaglutide for diabetes management, discuss with your prescriber whether switching to Wegovy for weight loss is appropriate, or whether continuing your current diabetes medication is the better clinical choice.

Wegovy with Existing Medical Conditions

Patients with well-controlled type 2 diabetes can often use Wegovy safely, though blood sugar monitoring becomes especially important as weight loss and semaglutide's glucose-lowering effects may require adjustments to other diabetes medications [4]. Those taking insulin or sulfonylureas face increased hypoglycaemia risk and need careful dose titration under prescriber supervision.

If you have a history of pancreatitis, kidney disease, or diabetic retinopathy, your prescriber will weigh the benefits of weight loss against potential risks specific to your condition. These aren't absolute contraindications but require individualised clinical judgement and closer monitoring throughout treatment.

Wegovy Pricing and Long-Term Treatment Costs

At Cured Pharmacy, Wegovy is available from £79.00, with transparent pricing shown before you complete your clinical assessment. This upfront approach eliminates the frustration of hidden fees or surprise charges that only appear after consultation. Your final cost depends on the prescribed dose, with lower starting doses priced accordingly and maintenance doses reflecting the higher medication quantity.

Weight management with Wegovy is a long-term commitment rather than a short course of treatment. Clinical trials followed patients for 68 weeks, and real-world evidence suggests many people continue treatment for years to maintain weight loss [1]. When calculating costs, consider that the weekly injection replaces the need for multiple daily medications in some cases, and the health benefits of sustained weight loss — reduced cardiovascular risk, improved diabetes control, better joint health — often offset the medication expense over time.

We guarantee the lowest prices in the UK for genuine, licensed Wegovy. If you find a lower price from another UK-registered pharmacy for the same dose, we'll match it. This price promise, combined with free clinical consultations and no membership fees, makes Cured Pharmacy the most cost-effective option for patients seeking legitimate online access to weight loss treatments.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4
3. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/13799
4. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
5. National Institute for Health and Care Excellence. (2022). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. https://www.nice.org.uk/guidance/ta875
6. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management. Clinical guideline [CG189]. https://www.nice.org.uk/guidance/cg189

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine and its use must be supervised by an appropriately qualified healthcare professional.